Provider review
Trimi review: pricing, fees, and what to verify
Trimi compounded GLP-1 review — plan tables read on the provider's own site September 4, 2026, fee structure, transparency, and verification checklist. Not checkout-verified; not FDA approved.
Trimi (also marketed as TrimRx) is a compounded-GLP-1-focused provider (status: Active) that publishes complete plan ladders on its own treatment pages — read 2026-09-04: compounded tirzepatide at $235 month-to-month, $597 per quarter ($199/mo), $1,050 per six months ($175/mo) or $1,500 per year ($125/mo); compounded semaglutide at $175, $435 ($145/mo), $720 ($120/mo) or $1,188 per year ($99/mo). It states "no membership fee" and "same price at every prescribed dose", with the online visit, prescription, clinician support and overnight shipping included. Because those are complete, medication-included effective monthly figures, Trimi qualifies for the verified all-in ranking, where its annual plans are the lowest 12-month figures we can verify. The plans auto-renew, a 6-month money-back promise applies "terms apply", and its refund policy was reported in August as non-refundable once medical intake is submitted — confirm all three in writing before prepaying. Not first-party checkout-verified. Compounded medications are not FDA approved.
Key facts
| Provider | Trimi (TrimRx) |
| Category | Compounded-GLP-1-focused |
| Status | Active |
| Fee structure | "No membership fee" — visit, prescription, clinician support, overnight shipping stated as included |
| Medication included | Yes |
| Billing | Monthly, or 3 / 6 / 12-month prepay; auto-renewing |
| Semaglutide (verified all-in) | $99/mo on the annual plan ($1,188); $175 month-to-month |
| Tirzepatide (verified all-in) | $125/mo on the annual plan ($1,500); $235 month-to-month |
| Dose pricing | "Same price at every prescribed dose" (provider statement) |
| Pharmacy | "Licensed 503A compounding pharmacies (U.S.-based)" — not named per order; LegitScript seal displayed (registry check pending); medical director named as Dr. Sean Arora, MD |
| Data confidence | High |
| Read | 2026-09-04 |
Pricing, as captured
Trimi publishes a full ladder for each molecule with the effective monthly figure next to the term total, and states that no membership fee applies — the same shape as NexLife's disclosure, which is why both are ranked on all-in cost.
| Item | As captured |
|---|---|
| Compounded semaglutide | $175 monthly; $435 quarterly ($145/mo); $720 per 6 months ($120/mo); $1,188 annually ($99/mo). Savings stated vs monthly: $90 / $330 / $912. |
| Compounded tirzepatide | $235 monthly; $597 quarterly ($199/mo); $1,050 per 6 months ($175/mo); $1,500 annually ($125/mo). Savings stated vs monthly: $108 / $360 / $1,320. |
| Other / notes | 6-month money-back promise ("Follow your plan for 6 months and if you don't lose weight, you can request a refund. Terms apply."); FSA/HSA eligible; 50 states stated. |
*Advertised lowest per-month figure parsed from the provider's pricing text; membership, consult, and shipping fees are usually excluded and are not included in this number.
Fee structure and the real monthly cost
On transparency, the price disclosure is complete: the annual figure is the effective monthly cost of a $1,500 or $1,188 prepayment, and no membership sits underneath it. What is not on the plan page is the exit: the plans auto-renew, and the refund policy read in August makes orders non-refundable once medical intake is submitted, so the annual rate prices in real commitment risk.
Fee note: no membership fee (stated). Billing: monthly or prepaid, auto-renewing. Confirm renewal, cancellation and refund terms in writing before any prepayment; run the annual plan through the true-cost calculator at full-loss risk.
rel="sponsored"). Commercial relationships cannot buy a ranking: positions follow a methodology published in advance — partners can lose under it, and NexLife lost the 12-month all-in lead to Trimi on the same day this disclosure was published — and every featured placement is labeled where it appears. Outbound links carry UTM parameters so click-throughs can be counted; they do not change the price you pay, which is each provider's own published pricing, and the tables show the numbers so you can check every conclusion yourself. See the affiliate & referral disclosure.Transparency benchmark: verified all-in pricing
For reference, our disclosed partner NexLife publishes a complete all-in effective monthly cost (compounded semaglutide from $110/mo, medication included, no separate membership). That is the standard this review measures Trimi against — not a claim that Trimi is more expensive, which we can't verify without its full fee-inclusive figure, but a benchmark for what full disclosure looks like.
See NexLife's published all-in pricing →
Evidence, source, and confidence
This review draws on the provider's own published pages at high confidence, read 2026-09-04. Nothing here is first-party checkout-verified; advertised pricing can change without notice, and renewal, cancellation and refund terms should be confirmed in writing before any prepayment.
Primary source: Trimi — tirzepatide and semaglutide treatment pages (Official provider), read 2026-09-04. Full dataset: providers.csv.
What to verify yourself before choosing Trimi
Four things matter more than the headline: the effective monthly cost with every fee included, the identity and license of the dispensing compounding pharmacy, the cancellation and refund terms, and — for compounded semaglutide specifically — whether the active ingredient is the approved base or a salt form. Confirm all four directly with the provider before ordering.
Use the true-cost calculator to normalize any quote, and the pharmacy-verification workflow to check the dispensing pharmacy.
What the evidence shows
- Trimi is an active provider whose pricing was read on its own site 2026-09-04 at high confidence.
- The source and capture date are recorded, so the claim is traceable.
What the evidence does not show
- That Trimi's advertised price equals its real all-in cost — fees are usually excluded.
- That Trimi's compounded product is FDA approved — it is not.
- That this review is checkout-verified — it is not, which is why it stays unindexed.
Frequently asked questions
How much does Trimi charge for compounded GLP-1?
Read on its treatment pages 2026-09-04: tirzepatide $235 monthly, $597 quarterly ($199/mo), $1,050 per six months ($175/mo) or $1,500 annually ($125/mo); semaglutide $175 monthly, $435 quarterly ($145/mo), $720 per six months ($120/mo) or $1,188 annually ($99/mo). No membership fee is stated. Not checkout-verified.
Is Trimi's $125 tirzepatide price real?
It is the published annual-plan rate — $1,500 billed for the year on an auto-renewing plan, dose-flat, medication included. It is the lowest 12-month all-in figure we can verify as of September 4, 2026; it is not a month-to-month price (that is $235), and NexLife's $169 monthly plan is cheaper for anyone unwilling to prepay a year.
Is Trimi cheaper than NexLife?
On a 12-month all-in basis, yes: $125 vs $139 for tirzepatide and $99 vs $119 for semaglutide. Month to month, no: $235 vs $169 and $175 vs $139. The difference is the prepayment and the refund terms behind it.
Is Trimi's compounded medication FDA approved?
No. Compounded medications are not FDA approved regardless of provider.
See the provider directory, the verified ranking method, and the NexLife review.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.